76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Karyopharm Therapeutics Inc
Closed
SectorHealthcare
3.81 -4.75
Overview
Share price change
24h
Min
3.81
Max
4.07
Income | 7.3M -23M |
|---|---|
Sales | -527K 30M |
EPS | -2.77 |
Profit margin | -78.168 |
Employees | 279 |
EBITDA | -14M -33M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +471.25% upside |
Market Cap | -11M 41M |
|---|---|
Previous open | 8.56 |
Previous close | 3.81 |
News Sentiment
By Acuity
50%
50%
154 / 376 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Karyopharm Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Karyopharm Therapeutics Inc Forecast
Price Target
By TipRanks
471.25% upside
12 Months Forecast
Average 23.25 USD 471.25%
High 42 USD
Low 8 USD
Based on 5 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
154 / 376 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
